First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations worldwide to offer an up-to-date and robust analysis of the effectiveness and practical use of available DMARDs – from conventional agents such as methotrexate to biologics and Janus … Read more
Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study that paves the way for new precision medicine approaches, particularly for older patients. Lung cancer primarily affects older individuals. Despite this, many laboratory studies rely on … Read more
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs. … Read more
Sildenafil – an active ingredient also marketed under the name of Viagra – improves symptoms in patients with Leigh syndrome. This has now been reported in the Cell journal by researchers at Charité – Universitätsmedizin Berlin, together with teams from Heinrich Heine University Düsseldorf (HHU), University Hospital Düsseldorf (UKD), and the Fraunhofer Institute for Translational Medicine … Read more
A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international team of scientists from institutions including Sun Yat-sen University and The Chinese University of Hong Kong, identified the RNA N⁶-methyladenosine (m⁶A) reader insulin-like growth factor 2 mRNA-binding … Read more
This trend is observed both in Canada and in other countries such as the United States,… The post ADHD Prescriptions Rising: What’s Driving the Increase? appeared first on Archynetys. Source link
Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S. VanNieuwenhze, PhD, FRSC, University Distinguished Professor and chair of the Department of Biology, along with Baylor doctoral students and a colleague at Texas Tech University Health Sciences … Read more
A major study of US veterans suggests that GLP-1 diabetes medications may influence addiction-related outcomes, revealing a surprising connection between metabolic treatments and substance use risk. Study: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. Image Credit: Kotcha K / Shutterstock A recent study … Read more
Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management. These medications are clearly effective. They stimulate the release of insulin and … Read more
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor’s genetic profile. This represents … Read more